Escalating Irinotecan (CPT-11) Administered 24 Hours Prior To Gemcitabine In Patients With Refractory Solid Tumors

Trial Profile

Escalating Irinotecan (CPT-11) Administered 24 Hours Prior To Gemcitabine In Patients With Refractory Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2010

At a glance

  • Drugs Gemcitabine (Primary) ; Irinotecan (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Sep 2010 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 30 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top